Alterations in alternative splicing are commonly reported in various cancers with involving genes exemplified by p53 and PTEN [23], BRCA1 [24], and PRMT2 [25] in breast cancer, TIMP1 and CD44 in colon cancer [26], Bcl-xL and CD44 [27] in lung cancer, and calpain 3 in melanoma [28]. This evidence concerns the gene CD44 and lung carcinoma.